Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.
News
All News
Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.
Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.
Share with us the topics you want to learn more about at Elevate-Derm West.
The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.
Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.
The novel systemic review compared results and adverse events associated with various treatment methods.
These findings can help clinicians better treat the psychosocial factors associated with the disease.
We want to know: Will you be attending the conference in Scottsdale later this week?
A post hoc analysis of OLYMPIA 1 and 2 trial data found significant improvement in the first 14 days of treatment.
The target action review date has been pushed to March 12, 2025.
4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.
As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.
Researchers noted that ethical use of AR and VR in cosmetic care requires balancing technological benefits with patient safety and privacy.
The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.
Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.
Learn more about the in-depth topics covered in the October 2024 acne supplement of Dermatology Times.
The minocycline hydrochloride extended release capsules (40 mg) represent a new standard of care for patients with rosacea.
Clinical trial exit interviews reveal detailed perspectives on disease burden for patients with chronic hand eczema.
VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.
Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.
Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.
Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.
After 1year of dupilumab treatment, researchers reported 76.5% of patients achieved CR, with further improvement to 85.6% after 3 years.
Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.
The phase 2a trial demonstrated the systemic treatment’s tolerable safety profile for patients with chronic and progressive hair loss.
Learn more about the in-depth topics covered in the October 2024 print issue of Dermatology Times.
Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.
Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.
Dermatology Times is looking back on the top stories in dermatology from the month of October.
